Chapter 5 - schizophrenia.life

About Cannabis

Cannabis, derived from the Cannabis sativa and Cannabis indica plants, has been used for thousands of years both as a material and as a psychoactive drug.

Cannabinoids are a group of substances found in the cannabis plant. The main cannabinoids are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Besides THC and CBD, more than 100 other cannabinoids have been identified.

Notably, the words “cannabis” and “marijuana” are often used interchangeably, but they don’t mean the same thing. “Cannabis” refers to all products from the Cannabis sativa plant, while “marijuana” specifically includes parts with significant THC, the compound responsible for its psychoactive effects.

The most active compound in cannabis is delta-9-tetrahydrocannabinol (THC), which is known for producing a euphoric “high”.

It is important to know that THC can also trigger short-lived psychotic symptoms, even in individuals without schizophrenia disorder.

Subchapter 1.

Cannabis use and schizophrenia

Subchapter 2.

Recognizing cannabis use disorder

Subchapter 3.

How does cannabis use impact schizophrenia?

Subchapter 4.

How does cannabis use disorder impact schizophrenia treatment?

References

McLoughlin BC, Pushpa-Rajah JA, Gillies D, Rathbone J, Variend H, Kalakouti E, et al. Cannabis and schizophrenia. Cochrane Database of Systematic Reviews [Internet]. 2014 Oct 14;(10). Available from: https://pubmed.ncbi.nlm.nih.gov/25314586/

Chesney E, Lawn W, McGuire P. Assessing Cannabis Use in People with Psychosis. Cannabis and cannabinoid research [Internet]. 2023 Nov 16;9(1):49–58. Available from: https://pubmed.ncbi.nlm.nih.gov/37971872/

Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. Schizophrenia Bulletin [Internet]. 2016 Feb 15;42(5):1262–9. Available from: https://pubmed.ncbi.nlm.nih.gov/26884547/

Di Forti M, Quattrone D, Freeman T, Tripoli G, Gayer-Anderson C, Quigley H. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study. The Lancet Psychiatry [Internet]. 2019 May;6(5):427–36. Available from: https://www.thelancet.com/article/S2215-0366(19)30048-3/fulltext

Swendsen J, Ben-Zeev D, Granholm E. Real-Time Electronic Ambulatory Monitoring of Substance Use and Symptom Expression in Schizophrenia. American Journal of Psychiatry [Internet]. 2011 Feb;168(2):202–9. Available from: https://pubmed.ncbi.nlm.nih.gov/21078705/

Kosty DB, Seeley JR, Farmer RF, Stevens JJ, Lewinsohn PM. Trajectories of cannabis use disorder: risk factors, clinical characteristics and outcomes. Addiction [Internet]. 2016 Sep 22;112(2):279–87. Available from: https://pubmed.ncbi.nlm.nih.gov/27515021/

Hasin DS, O’Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, et al. DSM-5 criteria for substance use disorders: Recommendations and rationale. American Journal of Psychiatry [Internet]. 2013;170(8):834–51. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3767415/

Hjorthøj C, Compton W, Starzer M, Nordholm D, Einstein E, Erlangsen A, et al. Asso schizophrenia stronger in young males than in females. Psychological Medicine [Internet]. 2023 May 4;53(15):1–7. Available from: https://pubmed.ncbi.nlm.nih.gov/37140715/

Dinis-Oliveira RJ. Metabolomics of Δ9-tetrahydrocannabinol: implications in toxicity. Drug Metabolism Reviews [Internet]. 2016 Jan 2;48(1):80–7. Available from: https://pubmed.ncbi.nlm.nih.gov/26828228/

Scheffler F, Phahladira L, Luckhoff H, du Plessis S, Asmal L, Kilian S, et al. Cannabis use and clinical outcome in people with first-episode schizophrenia spectrum disorders over 24 months of treatment. Psychiatry Research [Internet]. 2021 Aug;302:114022. Available from: https://pubmed.ncbi.nlm.nih.gov/34052461/

Ahmed S, Roth RM, Stanciu CN, Brunette MF. The Impact of THC and CBD in Schizophrenia: A Systematic Review. Frontiers in Psychiatry [Internet]. 2021 Jul 23;12. Available from: https://pubmed.ncbi.nlm.nih.gov/34366924/

Kayir H, Ruffolo J, McCunn P, Khokhar JY. The Relationship Between Cannabis, Cognition, and Schizophrenia: It’s Complicated. Cognitive Functioning in Schizophrenia: Leveraging the RDoC Framework [Internet]. 2022;437–61. Available from: https://pubmed.ncbi.nlm.nih.gov/36318403/

Johnson K, Weldon AJ, Burmeister MA. Differential effects of cannabis constituents on schizophrenia-related psychosis: a rationale for incorporating cannabidiol into a schizophrenia therapeutic regimen. Frontiers in psychiatry [Internet]. 2024 Apr 23;15. Available from: https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1386263/full

Christoph Felix Mosandl, Baltes-Flückiger L, Kronschnabel J, Meyer M, Guessoum A, Herrmann O, et al. Cannabis use and its association with psychopathological symptoms in a Swiss adult population: a cross-sectional analysis. Frontiers in Public Health [Internet]. 2024 May 22 [cited 2024 Aug 8];12. Available from: https://www.frontiersin.org/journals/public-health/ articles/10.3389/fpubh.2024.1356988/full

Hall W, Manthey J, Stjepanović D. Cannabis use and cannabis use disorders and their treatment in the Europe. European Archives of Psychiatry and Clinical Neuroscience [Internet]. 2024 Mar 15;275:307–13. Available from: https://link.springer.com/article/10.1007/s00406-024-01776-1

Hjorthoj C, Baker A, Fohlmann A, Nordentoft M. Intervention Efficacy in Trials Targeting Cannabis Use Disorders in Patients with Comorbid Psychosis Systematic Review and Meta-analysis. Current Pharmaceutical Design [Internet]. 2014 May 31 [cited 2019 Jun 8];20(13):2205–11. Available from: https://pubmed.ncbi.nlm.nih.gov/23829367/

Szerman N, Vega P, Roncero C, Peris L, Grau-López L, Basurte-Villamor I. Cariprazine as a maintenance treatment in dual schizophrenia: a 6-month observational study in patients with schizophrenia and cannabis use disorder. International Clinical Psychopharmacology [Internet]. 2024 Sep 25 [cited 2025 Jul 11];40(3):167–75. Available from: https://pubmed.ncbi.nlm.nih.gov/39319529/